VTRSHealthcare · Drug Manufacturers - Specialty & GenericThe 12 Wall Street analysts covering Viatris, Inc. hold a median 12-month price target of $20 — +0.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 100 of 100 as at 7 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Viatris, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Quality (74): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Size (9): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on VTRS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +0.4% from it.
Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Nov 2026 | JP Morgan | Maintains | Neutral | — |
| 6 Nov 2026 | JP Morgan | Maintains | Neutral | $20 → $21 |
| 26 Oct 2026 | Piper Sandler | Maintains | Neutral | $13 → $14 |
| 21 Oct 2026 | JP Morgan | Maintains | Neutral | $18 → $20 |
| 5 Oct 2026 | UBS | Maintains | Buy | $23 → $26 |
| 5 Oct 2026 | UBS | Maintains | Buy | — |
| 23 Sept 2026 | Oppenheimer | Initiates | Outperform | — |
| 23 Sept 2026 | Oppenheimer | Initiates | Outperform | $25 |
| 16 Sept 2026 | Piper Sandler | Maintains | Neutral | $12 → $13 |
| 16 Sept 2026 | Piper Sandler | Maintains | Neutral | — |
| 9 Sept 2026 | Leerink Partners | Initiates | Outperform | $20 |
| 9 Sept 2026 | Leerink Partners | Initiates | Outperform | — |
| 8 Sept 2026 | Argus Research | Maintains | Buy | — |
| 8 Sept 2026 | Argus Research | Maintains | Buy | $15 → $20 |
| 19 May 2026 | Barclays | Maintains | Overweight | $17 → $22 |
| 19 May 2026 | Barclays | Maintains | Overweight | — |
| 8 May 2026 | JP Morgan | Maintains | Neutral | — |
| 8 May 2026 | Truist Securities | Maintains | Buy | — |
| 24 Mar 2026 | Barclays | Maintains | Overweight | — |
| 28 Jan 2026 | Piper Sandler | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
VTRS appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 6 Nov 2026, Viatris, Inc. returned +103.8% against +10.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 3% of US stocks
Cheaper than 57% of US stocks
Cheaper than 48% of US stocks
Cheaper than 44% of US stocks
Higher than 28% of US stocks
Higher than 42% of US stocks
Higher than 47% of US stocks
Higher than 70% of US stocks
Higher than 24% of US stocks
Higher than 39% of US stocks
Higher than 65% of US stocks
Higher than 82% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Viatris, Inc. has a market value of $22.9B and an enterprise value of $34.4B.
Revenue in the twelve months to 30 June 2026: $14.7B. The latest quarter shrank 0.3% year on year.
Net income over the same four quarters: −$410.7M, a −2.8% net margin.
Diluted earnings per share, trailing twelve months: $−0.36.
Free cash flow in the twelve months to 30 June 2026: $1.8B, after $376.0M of capital spending.
Viatris, Inc. spent $300.1M on share buybacks and $557.5M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 235.8×; forward P/E: 7.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 2.41%, paying out 960% of earnings.
Viatris, Inc. employs 30,000 people — $491K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Viatris, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research highlights Viatris as a top-ranked value stock and describes its Style Scores as a feature of its Premium research service for evaluating stocks across value, growth, and momentum styles.
Why it matters — VTRS watchers may note the article’s favorable value-stock ranking and its focus on Zacks’ stock-screening framework.
Kahn Swick & Foti, LLC is investigating the adequacy of the price and process in Viatris’ proposed acquisition of Pacira BioSciences. The proposed terms provide Pacira shareholders $36.50 in cash per share.
Why it matters — The investigation concerns the terms and process of a proposed transaction involving Viatris.
The item says Viatris’ headline Q3 numbers cover the quarter ended September 2026 and frames a comparison of key metrics with Wall Street estimates and year-ago actuals. It does not provide the metrics or comparison results.
Why it matters — Those comparisons would help VTRS watchers assess quarterly performance, but the excerpt does not state their outcomes.
Seeking Alpha published a transcript of Viatris Inc.’s Q3 2026 earnings call. The excerpt provides no details about the discussion or results.
Why it matters — VTRS watchers may consult the transcript for management’s remarks, but the supplied excerpt contains no further information.
Viatris beat Q3 earnings estimates on stronger margins and raised its 2026 earnings guidance. Revenue fell year over year and missed estimates amid persistent supply constraints.
Why it matters — VTRS watchers may note the earnings and guidance gains alongside weaker revenue and ongoing supply constraints.
The 12 Wall Street analysts covering Viatris, Inc. have a median 12-month price target of $20, with estimates ranging from $14 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Viatris, Inc., 7 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Viatris, Inc. 100 out of 100 across roughly 4,600 US stocks as at 7 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 7 Nov 2026, Viatris, Inc. ranks 100 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +0.4% from the last close, and Ticker Nerd's factor model ranks Viatris, Inc. 100 out of 100 as at 7 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Viatris, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VTRS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $26 over the next 12 months.
Viatris, Inc. returned +103.8% over the 12 months to 6 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Viatris Inc. is a global healthcare company that develops, manufactures, and markets prescription medicines across a broad range of therapeutic areas.
The most recent item we track (Zacks Investment Research, 6 Nov 2026): "Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy?". Zacks Investment Research highlights Viatris as a top-ranked value stock and describes its Style Scores as a feature of its Premium research service for evaluating stocks across value, growth, and momentum styles.
Viatris Inc. is a global healthcare company that develops, manufactures, and markets prescription medicines across a broad range of therapeutic areas. Its portfolio includes branded medicines, generic drugs, complex generics, and biosimilars, serving patients and healthcare providers in developed and emerging markets. The company also supplies active pharmaceutical ingredients used in pharmaceutical manufacturing and supports access to medicines through broad commercial and distribution capabilities. Viatris Inc. operates across regions including North America, Europe, Greater China, Japan, Australia, New Zealand, Latin America, Africa, and the Middle East. Its products address conditions in areas such as cardiovascular health, infectious diseases, central nervous system disorders, immunology, and oncology. By combining established brands with off-patent and technically complex medicines, Viatris Inc. occupies an important role in the global pharmaceutical market, helping manufacturers, healthcare systems, and patients access a wide range of essential treatments.
CEO Mr. Scott Andrew Smith Ph.D. · 30,000 employees · United States · https://www.viatris.com
